News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
Boehringer Ingelheim Release: American Thoracic Society 2017 Spiriva Respimat Improves Breathing For People With Asthma Regardless Of BMI Or Allergic Status 5/23/2017
Novartis AG (NVS)' New Analyses Reinforce The Potential Of Ultibro Breezhaler For COPD Patients Historically Treated With Steroids 5/23/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/22/2017
Amgen (AMGN) Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects 5/22/2017
Meet The New CEO Of The Dutch Biotech Making A Cure For Blood Cancer 5/22/2017
Octapharma AG Underlines Strong Commitment To Haemophilia A Patients With The Publication Of New Clinical Data On PK-Guided Personalized Prophylaxis According To The Nupreviq Approach With Nuwiq 5/22/2017
Otsuka Pharma Announces Results Of Phase III Data On Tolvaptan 5/22/2017
Nexstim Updates The Timeline For Its Supplementary E-FIT Phase III Trial In Stroke Rehabilitation 5/19/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
Aurinia (AUPH) Doses First Patient In AURORA Phase III Clinical Trial Of Voclosporin In Lupus Nephritis 5/18/2017
Novartis AG (NVS) Data At ASCO, ICML And European Hematology Association Meetings Demonstrate Meaningful Advancements In Cancer Care 5/18/2017
Genmab A/S (GEN.CO) Announces Plans For New Studies Of Daratumumab 5/18/2017
Novo Nordisk A/S (NVO) Release: Early Response To Saxenda Resulted In Weight Maintenance And Additional Weight Loss Over 56 Week 5/17/2017
Promore Pharma Files Phase III Clinical Trial Application In India 5/17/2017
Can-Fite BioPharma (CFBI) Files Clinical Trial Application In Canada For Piclidenoson Ahead Of Upcoming Acrobat Rheumatoid Arthritis Phase III Study 5/16/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study 5/15/2017
Mologen (MOLGF.PK): Recruitment Goal Achieved For The Pivotal IMPALA Study With Lefitolimod In Colorectal Cancer Patients 5/15/2017
OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017 5/15/2017
PhotoCure: Phase III Study Investigating Blue Light Flexible Cystoscopy With Cysview In Surveillance Setting Meets Primary Endpoint 5/12/2017
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Orphazyme Completes Enrollment Of Patients For Phase III Clinical Trial In Niemann-Pick Type C Disease 5/11/2017
Results Of The J-ALEX Study For Chugai Pharma's Alecensa Are Published In "The Lancet" Online 5/11/2017
VBL Therapeutics (VBLX) Presents Data On VB-111 In Combination With Checkpoint Inhibitor At The 20th Annual ASGCT Meeting 5/11/2017
AstraZeneca PLC (AZN)'s Asthma Drug Fails to Meet Primary Endpoint in Late-Stage Trial 5/10/2017
Auris Med (EARS) Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study 5/9/2017
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Delayed Decline In Several Health-Related Quality Of Life Scales Compared To Temozolomide Alone For Newly Diagnosed Glioblastoma Patients 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Teva (TEVA), Active Biotech (BTPC) Suffer Another Setback After Laquinimod Flunks MS Study 5/8/2017
Faron Pharmaceuticals Ltd. Release: Update On Interest Phase III Study For Traumakine In Ards From IDMC 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
GlaxoSmithKline (GSK) Release: Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care 5/5/2017
European Society For Medical Oncology (ESMO) - Osimertinib Improves Symptoms In Advanced Lung Cancer Patients 5/5/2017
Otsuka Pharma And Lundbeck (LUN.CO) Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia 5/2/2017
Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck (LUN.CO), Otsuka Pharma Investors Unsettled 5/2/2017
Ablynx (ABLYF) Completes Patient Recruitment In Its Phase III Hercules Study Of Caplacizumab For The Treatment Of aTTP 5/2/2017
Genmab A/S (GEN.CO) Announces New Phase III Combination Study Of Daratumumab In Multiple Myeloma 4/28/2017
Teva Canada (TEVA) Announces Publication Of ARM-TD Study Results In Neurology For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 4/27/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed 4/27/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness 4/27/2017
PhotoCure: Late-Breaking Plenary Presentation At The American Urological Association 2017 Annual Meeting On Blue Light Flexible Cystoscopy With Hexaminolevinulate Phase III Study 4/26/2017
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program 4/25/2017
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board 4/25/2017
ObsEva (OBSV) Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids 4/25/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Sirtex Medical (SRX.AX) Release: SIR-Spheres Y-90 Resin Microspheres Substantially Improves Quality Of Survival In Primary Liver Cancer, New Study Against Standard Treatment Shows 4/24/2017
New Microbiology Data From Paratek Pharma (PRTK) Show Omadacycline Effective Against Most Common Skin Infections And Pathogens, Including MRSA 4/24/2017
New Health Economics Studies Highlight The Potential For Paratek Pharma (PRTK)’ Omadacycline To Provide Cost-Savings Compared To Standard Of Care For The Treatment Of Patients With Acute Bacterial Skin And Skin Structure Infections 4/24/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/24/2017
Auris Med (EARS) Reports Key Results From Keyzilen AMPACT2 Open-Label Extension Study 4/24/2017
Basilea (BSLN.SW) Announces Agreement With FDA On Special Protocol Assessments For Antibiotic Ceftobiprole Phase III Clinical Studies In Bloodstream And Skin Infections 4/21/2017
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM 4/21/2017
Gamida Cell Announces Publication Of Positive Clinical Outcomes From NiCord-Transplanted Patients In The Journal Of Biology Of Blood And Marrow Transplantation 4/20/2017
GNT Biotech and Medicals Corporation To Begin Phase III Clinical Trial In Taiwan Of Epigenetic Regulator Chidamide For Late-Stage Breast Cancer 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
GW Pharma (GWPH) And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (Cannabidiol) Data Released By The American Academy of Neurology 4/19/2017
Ultragenyx (RARE), Kyowa Hakko Kirin And Kyowa Kirin International Announce Positive 24-Week Data From Adult Phase II Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia 4/19/2017
NovoCure Announces Four Presentations On Tumor Treating Fields At American Academy of Neurology Annual Meeting In Boston 4/19/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
NovoCure Release: CNS Oncology Publishes Data Suggesting Survival Benefit Of Optune In Combination With Second Line Chemotherapies After Glioblastoma Recurrence 4/17/2017
Genentech (RHHBY) Shows Off Late-Stage Hemophilia A Data 4/17/2017
ASIT Biotech Presents Its 2016 Annual Results And Recent Updates In Clinical Developments 4/12/2017
Saniona's Partner, Medix, Obtains Approval To Initiate Phase III Study In Obesity 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Nabriva Announces Enrollment Completion For LEAP 1, A Phase III Clinical Trial Evaluating Lefamulin In Community-Acquired Bacterial Pneumonia 4/11/2017
Chugai Pharma's Alecensa Met Its Primary Endpoint In The ALEX Study 4/10/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
Takeda (TKPYY) Completes Enrollment Of More Than 20,000 Children And Adolescents In Global Phase III Trial Of Dengue Vaccine Candidate 4/5/2017
OSE Immunotherapeutics Presented New Data At AACR Annual Meeting 2017 On OSE-172 (Effi-DEM), Company's Checkpoint Inhibitor Blocking Suppressive Myeloid Cells And Inducing Antitumoral Potent T Memory Response 4/5/2017
UroGen Announces Enrollment Of First Patient In Phase III Clinical Trial Of Mitogel For Treatment Of Low-Grade Upper Tract Urothelial Carcinoma 4/3/2017
AstraZeneca PLC (AZN) Release: LYNPARZA (Olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy 3/30/2017
Intec Pharma Provides Update On Phase III ACCORDANCE Study Of The Accordion Pill Carbidopa/Levodopa In Parkinson's Disease Patients 3/29/2017
GW Pharma (GWPH) Announces Epidiolex Receives Orphan Drug Designation From The European Medicines Agency For The Treatment Of Lennox-Gastaut Syndrome 3/29/2017
Allergan (AGN) And Paratek Pharma (PRTK) Announce Positive Results From Two Phase III Trials Of Sarecycline For The Treatment Of Moderate To Severe Acne 3/27/2017
3 Of The Most Promising Diabetes Meds From 5 Of The Most Innovative Biotechs In The World 3/27/2017
Almirall And Sun Pharma (SUNPHARMA.NS) Announce Regulatory Filing Of Tildrakizumab In Europe 3/24/2017
Breaking The Cold Chain: New Vaccine Doesn't Need Refrigeration 3/23/2017
Gamida Cell Receives Additional EMA Orphan Drug Designation For Nicord In Haematopoietic Stem Cell Transplantation (HSCT) 3/23/2017
Nanobiotix: The Independent Data Monitoring Committee Recommends The Continuation Of The Ongoing Phase II/IIITrial Of Nbtxr3 In Soft Tissue Sarcoma 3/23/2017
Onxeo To Present Data Supporting Three Key Orphan Oncology Assets At AACR Annual Meeting 3/22/2017
Boehringer Ingelheim Phase III Study Now Enrolling Patients With Progressive Fibrosing Lung Diseases 3/20/2017
Alkermes (ALKS) Initiates Phase III Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 3/16/2017
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase III Clinical Study Evaluating JZP-258 For The Treatment Of Cataplexy And Excessive Daytime Sleepiness In Narcolepsy 3/16/2017
PHARNEXT Announces Initiation Of Phase III Extension Study PLEO-CMT-FU Of PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A 3/16/2017
AstraZeneca PLC (AZN) Steals Tesaro (TSRO)'s PARP Thunder With Phase III Ovarian Cancer Data 3/16/2017
AbbVie (ABBV) Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017
One Death in the HAVEN 1 Trial Complicates Roche (RHHBY)’s Entry into the Hemophilia A Market 3/13/2017
DBV Tech Announces Completion Of Enrollment Of The REALISE Study In Peanut Allergic Children 3/10/2017
TiGenix Announces Positive Topline Week-104 Data For Cx601 ADMIRE-CD Trial 3/9/2017
Aurinia (AUPH) Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Highlights 3/9/2017
DalCor's Phase III Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule 3/7/2017
ObsEva (OBSV) Starts Phase III Clinical Program For Nolasiban In ART 3/7/2017
Not Giving Up: Roche (RHHBY) To Start New Phase III Tests With Once-Failed Alzheimer's Drug 3/7/2017
Chinese Billionaire's Biotech Hutchison China MediTech (Chi-Med) Shows Off Phase III Cancer Drug Data 3/6/2017
GlaxoSmithKline (GSK)'s MUSCA Study Shows Nucala (Mepolizumab) Significantly Improves Quality Of Life And Lung Function In Severe Asthma Patients With An Eosinophilic Phenotype 3/6/2017
Advanced Accelerator Applications Announces Presentation Of Quality Of Life Findings From NETTER-1 Phase III Study At ENETS 3/6/2017
10 Biotechs With an Orphan Drug in Late-Stage Pipeline 3/3/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
MorphoSys AG Announces That Its Licensee Janssen R&D Has Reported New Data From Two Phase III Studies Of Guselkumab In Plaque Psoriasis 3/3/2017
Genentech (RHHBY) New Breast Cancer Cocktail Cuts Deaths in Phase III Study, Roche (RHHBY) Stock Soars 3/3/2017
NovoCure Announces Data Presentations At The AACR Annual Meeting 2017 3/2/2017
Gamida Cell Announces First Patient Transplanted In Phase III Registration Study Of Nicord For Blood Cancers 2/28/2017
Atlantic Healthcare Confirms Alicaforsen Targets TLR-9, Providing A Second Mechanism Of Action To Treat New And Existing Inflammatory Indications 2/28/2017
ASIT Biotech Reports Positive Results In Its Phase III Clinical Trial With Gp-ASIT+ For Grass Pollen Induced Allergic Rhinitis 2/28/2017
ALK-Abello A/S's ACARIZAX Data Results In Significant Change To The GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended As A Treatment Option In Patients With House Dust Mite Allergic Asthma 2/27/2017
Shire (SHPG) Release: CHMP Recommends EU Conditional Marketing Authorisation For Natpar (Parathyroid Hormone) For Patients With Chronic Hypoparathyroidism 2/27/2017
ASIT Biotech Will Publish The Results Of The Phase III Clinical Trial With Its Gp-ASIT+ Product Candidate For Treating Grass Pollen Rhinitis On 28 February, 2017 2/27/2017
NoNO, Inc Initiates Phase III Study Of NA-1 For Acute Ischemic Stroke 2/27/2017
Auris Med (EARS) Receives FDA Fast Track Designation For AM-111 In Acute Sensorineural Hearing Loss 2/24/2017
Novartis AG (NVS)'s Cancer Drug Gets a Fast Track Ticket From the FDA 2/23/2017
VBI Vaccines Receives Positive Response From Health Canada’s Initial Evaluation Of The Proposed Sci-B-Vac Phase III Clinical Program 2/22/2017
GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 2/21/2017
AstraZeneca PLC (AZN) Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial 2/20/2017
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017
Takeda (TKPYY) And TiGenix Report New Data Highlighting Maintenance Of Long-Term Remission Of Complex Perianal Fistulas In Crohn’s Disease Patients With Cx601 2/17/2017
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug 2/17/2017
City of Hope To Manufacture NurOwn For BrainStorm Cell's Phase III ALS Clinical Trial 2/16/2017
Roche (RHHBY) Faces Off With Itself for $9 Billion Breast Cancer Drug Business 2/15/2017
First Patient Enrolled In NovoCure’s Phase III Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data 2/14/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis 2/13/2017
Neurocrine Biosciences (NBIX) Nabs North American Rights to Bial's ONGENTYS 2/10/2017
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017
Onxeo: Information On ReLive Trial Design And Role Of Its Data Safety And Monitoring Board 2/8/2017
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Mithra Pharmaceuticals Completes Recruitment For European Phase III Estelle Study 2/7/2017
Biofrontera AG Reports Positive Phase III Results For Ameluz In Combination With Daylight-PDT 2/7/2017
Why Struggling Alkermes (ALKS) Could Make a Comeback in 2017 2/7/2017
AstraZeneca PLC (AZN) Quietly Kills Some Programs 2/6/2017
Kiadis Pharma Issues Clinical And Regulatory Progress Update On ATIR101 And ATIR201 2/6/2017
Sobi - Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy Alprolix In Children With Haemophilia B Published In The Lancet Haematology 2/2/2017
Nabriva Confirms No Sample Size Adjustment Required For LEAP 1 Phase III Trial Of Lefamulin In Community Acquired Bacterial Pneumonia 2/2/2017
Motif BioSciences, Inc. Phase 3 Clinical Trial Finishes Patient Treatment Phase 1/31/2017
Celgene (CELG) Receives Positive CHMP Opinion To Expand REVLIMID (Lenalidomide) Indication As Monotherapy For The Maintenance Treatment Of Patients With Newly Diagnosed Multiple Myeloma (MM) After Autologous Stem Cell Transplantation 1/27/2017
Foresee Pharma Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer 1/27/2017
Myovant Release: Initiates Phase 3 Clinical Program Of Relugolix In Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids 1/25/2017
ImmuPharma plc (IMM.L) Release: Company Update On Lupuzor Pivotal Phase III Study Full Analysis Of Patient Recruitment 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer 1/24/2017
Onxeo Release: Company Completes Enrollment In Phase 3 Study Of Livatag For The Treatment Of Hepatocellular Carcinoma 1/24/2017
Actelion (ALIOF.PK) Release: Amid Takeover Talks With Johnson & Johnson (JNJ), The Company's Hypertension Drug Flunks Key Phase III Test 1/23/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing 1/19/2017
How This Israeli Biotech Could be a Threat to Celgene (CELG) 1/18/2017
AstraZeneca PLC (AZN) Release: Biopharma Rejigs Primary Endpoints for Mystic Lung Cancer Trial 1/17/2017
Alcobra (ADHD) Release: Company Stock Decimated As ADHD Drug Flunks Phase III Test 1/17/2017
Allergan (AGN), Gedeon Richter (RIG2.F) Release: Companies Show Off Late-Stage Uterine Fibroids Data 1/17/2017
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017
Shionogi Release: Pharma's Investigators are Prepping a FDA App for New Antibiotic After Positive Trial 1/13/2017
Starpharma Release: VivaGel BV Granted QIDP And Fast Track Designation By U.S. FDA 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Pluristem Therapeutics (PSTI) Release: Jumps as the FDA Clears Critical Limb Ischemia Trial 1/10/2017
RedHill Biopharma (RDHL) Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection 1/10/2017
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017
Alcobra (ADHD) Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program 1/9/2017
Sun Pharma (SUNPHARMA.NS) Announces Positive Topline Results Of Confirmatory Phase-3 Clinical Trial For Seciera For Treatment Of Dry Eye 1/4/2017
JAMA Publishes Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab Phase 3 Data 12/27/2016
BeiGene (BGNE) Starts Global Phase III Trial Of BTK Inhibitor 12/27/2016
Chugai Pharma's Bispecific Antibody "Emicizumab" For Hemophilia A Meets Primary Endpoint In Phase lll Study 12/22/2016
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III 12/22/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Psoriatic Arthritis 12/22/2016
After Failed Phase III, Auven to Terminate the KIACTA Program 12/21/2016
Octapharma AG Presents Key Data With Nuwiq In Previously Untreated Patients From The Nuprotect Study At American Society of Hematology (ASH) Annual Meeting In San Diego, USA 12/21/2016
Kiadis Pharma Provides Update On Second Dose Trial (CR-AIR-008) With ATIR101 12/21/2016
Akebia (AKBA) Forges $1B U.S. Deal with Otsuka Pharma on Late-Stage Drug 12/20/2016
Theravance Biopharma (TBPH) Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline (GSK) And Innoviva 12/20/2016
Janssen Sciences Ireland UC Release: Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen 12/20/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
Nabriva Achieves 60% Randomization Target In LEAP 1 Phase 3 Trial In Community Acquired Bacterial Pneumonia 12/20/2016
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis 12/20/2016
Primary Endpoint Met in ViiV Healthcare's Two Phase III Trials of Two-Drug HIV Treatment Regimen 12/20/2016
PHARNEXT Completes Patient Enrollment In International Pivotal Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 12/20/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index 12/19/2016
Grunenthal Receives Breakthrough Therapy Designation From U.S. FDA For Neridronic Acid For The Treatment Of CRPS 12/16/2016
Flamel Technologies (FLML) Doses First Patient In REST-ON Phase III Trial Of FT218 for Excessive Daytime Sleepiness & Cataplexy 12/16/2016
Dermira (DERM) Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis 12/8/2016
Regeneron (REGN) And Sanofi (SNY)i Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA 12/8/2016
Valeant (VRX) Announces Phase 3 Results For Psoriasis Treatment IDP-118 12/8/2016
Horizon Pharma (HZNP) Craters as Rare Neuromuscular Drug Flunks Late-Stage Study 12/8/2016
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016
China-Prevalent Form Of NSCLC Responds To AstraZeneca PLC (AZN) Drug 12/7/2016
Auris Med (EARS) On Track To Resume Enrollment Of Keyzilen Tinnitus Program Following Regulatory Feedback 12/6/2016
Celgene (CELG) Release: ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE For Challenging Patient Populations 12/6/2016
Theravance Biopharma (TBPH) Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline (GSK) And Innoviva 12/5/2016
GW Pharma (GWPH) Announces New Epidiolex® (CBD) Positive Phase III Data In Dravet Syndrome And Lennox-Gastaut Syndrome 12/5/2016
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
GW Pharma (GWPH) Announces Epidiolex (Cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting 12/1/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016
Santen Pharma Announces Phase III SAKURA Program Topline Results In Patients With Non-Infectious Uveitis Of The Posterior Segment 11/28/2016
Intec Pharma Enters Into Agreement With The Michael J. Fox Foundation Around Its Phase III Trial Recruitment 11/28/2016
ADImmune Corporation Begins Shipments To EU And Phase III Trial In Europe 11/23/2016
Galapagos (GLPG.BR) Release: Phase 3 Study With Filgotinib Initiated In Crohn's Disease 11/23/2016



//-->